1-4 of 4
Greg J. Ahmann
Close
Sort by
Journal Articles

Multiple myeloma cells’ capacity to decompose H 2 O 2 determines lenalidomide sensitivity

Sinto Sebastian, Yuan X. Zhu, Esteban Braggio, Chang-Xin Shi, Sonali C. Panchabhai, Scott A. Van Wier, Greg J. Ahmann, Marta Chesi, P. Leif Bergsagel, A. Keith Stewart, Rafael Fonseca
Journal: Blood
Blood (2017) 129 (8): 991–1007.
https://doi.org/10.1182/blood-2016-09-738872
Published: 2017
Includes: Supplemental data
Journal Articles

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone

Brief Report
Shaji K. Kumar, Hajime Uno, Susanna J. Jacobus, Scott A. Van Wier, Greg J. Ahmann, Kimberly J. Henderson, Natalie S. Callander, Jessica L. Haug, David S. Siegel, Philip R. Greipp, Rafael Fonseca, S. Vincent Rajkumar
Journal: Blood
Blood (2011) 118 (16): 4359–4362.
https://doi.org/10.1182/blood-2011-03-342089
Published: 2011
Journal Articles

Clinical implication of centrosome amplification in plasma cell neoplasm

Clinical Trials & Observations
Wee J. Chng, Greg J. Ahmann, Kim Henderson, Rafael Santana-Davila, Philip R. Greipp, Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Shaji Kumar, S. Vincent Rajkumar, John A. Lust, Robert A. Kyle, Steven R. Zeldenrust, Suzanne R. Hayman, Rafael Fonseca
Journal: Blood
Blood (2006) 107 (9): 3669–3675.
https://doi.org/10.1182/blood-2005-09-3810
Published: 2006
Journal Articles

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

Clinical Trials & Observations
Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Philip R. Greipp, Mark R. Litzow, Kimberly J. Henderson, Scott A. Van Wier, Greg J. Ahmann, Rafael Fonseca
Journal: Blood
Blood (2005) 106 (8): 2837–2840.
https://doi.org/10.1182/blood-2005-04-1411
Published: 2005